Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

Eli Lilly (LLY) will present 21 data sets at the 2026 Fall Clinical Dermatology Conference, highlighting treatments for atopic dermatitis, psoriasis, and alopecia areata. Key data include EBGLYSS (lebrikizumab-lbkz) for atopic dermatitis, Taltz (ixekizumab) and Zepbound (tirzepatide) for psoriasis and obesity, and Olumiant (baricitinib) for alopecia areata. The presentations aim to show durable disease control and reduced treatment frequency.

Original reporting
Published Oct 5, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions — source image
Decision brief

The 30-second read

$LLYBullishLow
01

Why it matters

The conference presentations represent the first public disclosure of detailed efficacy and safety data, which could influence analyst forecasts and investor sentiment.

02

Market read

First‑time data release may drive short‑term price movement in LLY and affect related dermatology biotech stocks.

03

What to watch

Potential regulatory or reimbursement hurdles for EBGLYSS in Europe could temper enthusiasm.

Relevance 7/10Novelty 8/10Timing: ahead of conference Oct 8‑11

Background

Lilly is expanding its dermatology portfolio with EBGLYSS (lebrikizumab) and exploring combination therapies with Taltz and Zepbound.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly (LLY) will present new dermatology data, including EBGLYSS at the 2026 Fall Clinical Dermatology Conference.

Expected impact

potential upside as investors price in favorable clinical results

Evidence & confidence

First disclosure of multiple poster presentations; data may improve expectations for EBGLYSS, Taltz/Zepbound combo and Olumiant.

Market effects

Dermatology and broader biotech sector may see modest uplift from positive data cues.

U.S. biotech equities could benefit; limited global effect.

Limited to investors tracking Lilly's pipeline.

Counterpoint

If data are incremental rather than breakthrough, the market may already price in expectations, limiting upside.

Key entities

  • Eli Lilly and Company

    US‑listed biopharma presenting new dermatology data.

  • EBGLYSS (lebrikizumab‑lbkz)

    Investigational biologic for atopic dermatitis.

Related articles

$LLYMed

Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

Eli Lilly's weight-loss drug, Zepbound, showed significant efficacy in a clinical trial for adolescents aged 12 to 17, with participants losing an average of 40 pounds. This could expand Zepbound's market to over 5 million U.S. patients, potentially adding $6.5 billion in annual revenue for Eli Lilly. The company's Q3 earnings showed strong growth, with Zepbound generating $5.4 billion in revenue.

$LLYMed

Eli Lilly Is Near Its High. Bank of America Sees Another 19%

Bank of America raised its price target for Eli Lilly to $1,600, citing strong revenue growth and potential in new drugs. Lilly's Q3 revenue grew 39%, and it raised its 2026 guidance to $91B-$92B. The stock is up 25% in 2026 but remains 7% below its recent high. Bank of America's target is based on Lilly's growth profile and upcoming drug developments.

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.